Salt Lake City, UTAH2 Active Studies

Multiple Myeloma Clinical Trials in Salt Lake City, UTAH

Find 2 actively recruiting multiple myeloma clinical trials in Salt Lake City, UTAH. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
720
Enrolling

Recruiting Multiple Myeloma Studies in Salt Lake City

About Multiple Myeloma Clinical Trials in Salt Lake City

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 2 multiple myeloma clinical trials recruiting participants in Salt Lake City, UTAH. These studies are seeking a combined 720 participants. Research is being sponsored by Rutgers, The State University of New Jersey, University of Alabama at Birmingham. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Salt Lake City — FAQ

Are there multiple myeloma clinical trials in Salt Lake City?

Yes, there are 2 multiple myeloma clinical trials currently recruiting in Salt Lake City, UTAH. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Salt Lake City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Salt Lake City research site will contact you about next steps.

Are clinical trials in Salt Lake City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Salt Lake City studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 2 active trials in Salt Lake City are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated March 2, 2026 from ClinicalTrials.gov